Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Meanwhile a myriad of studies using tissue
2022-06-06
Meanwhile a myriad of studies using tissue- and cell type-specific deletion of GPX4 have provided evidence that various tissues/cells, such as distinct neuronal cell populations including glutamatergic neurons of the forebrain [24], Purkinje cells of the cerebellum [74] and motor neurons [75], phot
-
MMV s distinct mode of inhibition addresses key impediments
2022-06-06
MMV019313's distinct mode of inhibition addresses key impediments in the development of PfFPPS/GGPPS inhibitors as antimalarial drugs. First, it is the first non-bisphosphonate inhibitor of Plasmodium FPPS/GGPPS with drug-like physicochemical properties satisfying the “Rule of 5” (Van Voorhis et al.
-
The FAAH inhibitor activity of the
2022-06-06
The FAAH inhibitor activity of the 3-(5-(ethoxycarbonyl)-1-phenyl-1H-pyrazol-3-yl)phenyl cyclohexylcarbamates was investigated by preparation of compounds (43–52, Table 3). These new compounds displayed an important loss of activity in comparison with the corresponding regioisomers 5-phenyl compound
-
We also intended to determine the possible mechanism underly
2022-06-06
We also intended to determine the possible mechanism underlying EZH2 upregulation in the PC. Although no recurrent mutations of EZH2 have been described in CLL [27, 28, 29], we aimed to rule out the possibility of activating mutations in the background of EZH2 overexpression. We detected no mutation
-
br Conclusion The addition of cellulose to natural substrate
2022-06-05
Conclusion The addition of methylergometrine to natural substrate increases the number of H-bonds which indicates an increase in the stability of the docking systems. The investigated compounds are more stable than natural substrate in docking systems, where the natural substrate has two H-bonds
-
Apamin br Amino acids The role of leucine
2022-06-05
Amino acids: The role of leucine Amino Apamin metabolism plays a central role in brain physiology, as several amino acids serve as biosynthetic precursors for neurotransmitter synthesis [36]. In addition, the amino acids L-leucine and L-lysine may participate in ketogenesis. For these reasons, su
-
BIIB021 receptor Differentiation to either Th or Th cells
2022-06-05
Differentiation to either Th1 or Th2 BIIB021 receptor is significantly influenced by the relative expression of T-bet and GATA-3, respectively (Zhu et al., 2006, Jenner et al., 2009). T-bet acts as a key regulator of Th1 cell fate determination and directly activates IFN-γ and suppresses IL-4 (Szab
-
NS 1738 br Evolution of multiple GnRH forms and GnRH recepto
2022-06-05
Evolution of multiple GnRH forms and GnRH receptors across vertebrates GnRH is an evolutionary ancient peptide that first appears prior to the protostome-deuterostome split, and is a member of the GnRH-adipokinetic hormone-corazonin superfamily of peptides (Roch et al., 2011, Roch et al., 2014).
-
Variants of NEIL were also analysed in Primary sclerosing
2022-06-05
Variants of NEIL1 were also analysed in Primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA) patients by Forsbring et al. to identify effect of variants on these diseases. Four variants were identified i.e., one earlier validated (G83D) and three novel (E181K, H275, R339W). E181K was fo
-
In this study for the first time the electrochemical
2022-06-05
In this study, for the first time: 1) the electrochemical glutamate oxidase-based biosensor was optimized for the determination of low micromolar glutamate concentrations; 2) the algorithm of the analysis of exocytotic and transporter–mediated glutamate release was developed; 3) the comparative anal
-
Glucagon was described as an insulin secretagogue as early
2022-06-05
Glucagon was described as an insulin secretagogue as early as 1965 (Samols et al., 1965). Our studies extend these findings by demonstrating that this is a direct effect mediated by distinct receptors in the mouse pancreas. Previous experiments on isolated β lorlatinib clearly show that glucagon is
-
GSK2194069 By measuring the accumulation of unprenylated Rap
2022-06-02
By measuring the accumulation of unprenylated Rap1a as a surrogate marker for the inhibition of FPPS [8], [9], [10], [11], we found that upregulation of FPPS expression in Hela cells reduced the accumulation of unprenylated Rap1a in response to 24h' treatment with 0–50μM ZOL. As expected, cells cult
-
br Materials and methods br Results br Discussion EZH
2022-06-02
Materials and methods Results Discussion EZH2 is a subunit of the polycomb repressive complex, which trimethylates lysine 27 on histone 3, a repressive marker for gene expression. EZH2 is important for cancer cell proliferation, migration, and invasion, all of which are associated with canc
-
Based on pharmacophore modeling a good HDAC inhibitor has
2022-06-02
Based on pharmacophore modeling, a good HDAC inhibitor has at least three sides/regions: the attachment side of the Zn2+ cofactor/HDAC active site (Zn2+ binding group/ZBG), hydrophobic cap (CAP) and linker containing connecting unit (CU) with electronegative groups (Mohan et al., 2011, Rossi et al.,
-
There is no doubt that GPR is
2022-06-02
There is no doubt that GPR55 is a LPI receptor; however, we should re-consider whether or not GPR55 is in fact another cannabinoid receptor. The pharmacologies of the GPR55 and CB1 receptors are complicated; CB1 inverse agonist/antagonists SR141716A (rimonabant) and AM251 were shown to be potent ago
15549 records 402/1037 page Previous Next First page 上5页 401402403404405 下5页 Last page